NASDAQ:CGON CG Oncology Q2 2024 Earnings Report $26.08 +1.13 (+4.53%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$26.06 -0.02 (-0.08%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast CG Oncology EPS ResultsActual EPS-$0.28Consensus EPS -$0.42Beat/MissBeat by +$0.14One Year Ago EPSN/ACG Oncology Revenue ResultsActual Revenue$0.11 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACG Oncology Announcement DetailsQuarterQ2 2024Date8/8/2024TimeBefore Market OpensConference Call DateThursday, August 8, 2024Conference Call Time6:00AM ETUpcoming EarningsCG Oncology's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 8, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CG Oncology Earnings Headlines1CGON : Beyond The Numbers: 7 Analysts Discuss CG Oncology StockJuly 16 at 9:37 PM | benzinga.comCGON - CG Oncology Inc Trailing Returns - MorningstarJune 26, 2025 | morningstar.comMA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.July 17 at 2:00 AM | American Alternative (Ad)CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)June 23, 2025 | seekingalpha.comCG Oncology stock price target raised to $56 from $52 at Morgan StanleyJune 18, 2025 | investing.comAugust 15th Options Now Available For CG Oncology (CGON)June 18, 2025 | nasdaq.comSee More CG Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email. Email Address About CG OncologyCG Oncology (NASDAQ:CGON) (NASDAQ: CGON) is a clinical-stage biotechnology company dedicated to the development of next-generation immuno-oncology therapies. The company’s core focus lies in leveraging novel oncolytic viral platforms and targeted immunomodulatory agents to activate the body’s immune system against solid tumors. Its lead candidate, CG0070, is an oncolytic adenovirus engineered to selectively replicate within and destroy bladder cancer cells while stimulating a localized immune response via granulocyte-macrophage colony-stimulating factor (GM‐CSF). In addition to its oncolytic virus pipeline, CG Oncology is advancing a proprietary immunomodulator licensed from European collaborators. This fusion protein is designed to bind tumor-associated superantigens and activate tumor-infiltrating T cells, broadening the company’s reach into multiple oncology indications. Together, these assets reflect a diversified strategy aimed at both direct tumor eradication and systemic immune activation. The company conducts multi-center clinical trials across North America and Europe, collaborating with leading academic institutions and contract research organizations to evaluate safety and efficacy in patients with advanced cancers. CG Oncology’s global approach enables rapid patient enrollment and regulatory engagement, positioning its candidates for potential registration in key markets. Founded in the early 2010s as a spinout focusing on oncolytic viral research, CG Oncology has grown under the leadership of an experienced management team with deep roots in biotechnology and pharmaceutical development. Supported by a board of directors with expertise spanning immunology, virology and oncology drug commercialization, the company continues to pursue strategic partnerships and funding opportunities to advance its pipeline toward commercialization.Written by Jeffrey Neal JohnsonView CG Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong Upcoming Earnings American Express (7/18/2025)HDFC Bank (7/18/2025)Coca Cola Femsa (7/18/2025)3M (7/18/2025)Southern Copper (7/18/2025)Charles Schwab (7/18/2025)Truist Financial (7/18/2025)NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
